CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Edgewise Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Edgewise Therapeutics Inc
1715 38Th St
Phone: 302-6365401p:302-6365401 BOULDER, CO  80301  United States Ticker: EWTXEWTX
Business Summary
Edgewise Therapeutics, Inc. is a biopharmaceutical company focused on cardiovascular diseases. The Company is advancing a cardiovascular pipeline targeting significant unmet needs, including hypertrophic cardiomyopathy, heart failure and other serious cardiovascular and cardio metabolic conditions. The Company's pipeline comprises the EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF and EDG-003. EDG-7500 is a novel, oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM) and other diseases of diastolic dysfunction which is being studied in a multipart Phase 2 trial for the potential treatment of obstructive and nonobstructive HCM. The Company is also developing EDG-15400, which is in a Phase 1 trial of healthy adults with the future disease target of heart failure with preserved ejection fraction (HFpEF).
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202612/31/2025YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board, Co-Founder Peter A.Thompson 66 8/1/2017 5/1/2017
President, Chief Executive Officer, Director KevinKoch 65 9/1/2020 6/1/2017
Chief Scientific Officer, Director, Co-Founder AlanRussell 56 8/1/2017 6/1/2017
8 additional Officers and Directors records available in full report.

General Information
Number of Employees: 154 (As of 3/31/2026)
Outstanding Shares: 107,593,006 (As of 4/30/2026)
Shareholders: 4
Stock Exchange: NASD
Federal Tax Id: 821725586
Fax Number: 302-6365454


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, July 15, 2026